PMID- 27774018
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1179-7266 (Print)
IS  - 1179-7266 (Electronic)
IS  - 1179-7266 (Linking)
VI  - 3
DP  - 2012
TI  - Partial response to proton pump inhibitor therapy for GERD: observational study 
      of patient characteristics, burden of disease, and costs in the USA.
PG  - 57-67
AB  - BACKGROUND: Disease burden and associated costs are not well understood among 
      patients with gastroesophageal reflux disease (GERD) who have persistent symptoms 
      despite optimized proton pump inhibitor (PPI) therapy. The aim of this study was 
      to investigate disease burden and costs of GERD in partial responders to PPI 
      therapy. METHODS: The Partial Response to PPI treatment: the Cost to Society and 
      the Burden to the Patient in the US (REMAIN US) study was a 12-month, 
      multicenter, noninterventional, observational study of 552 partial PPI responders 
      in the USA. Participating sites were comprised of family practice (n = 30), 
      internal medicine (n = 8), and specialist (gastroenterologist) centers (n = 15). 
      GERD symptoms, health-related quality of life (HRQL), and impact on productivity 
      were evaluated from patient-reported outcome instruments. Resource utilization 
      data were also collected. RESULTS: Patients had a high symptom burden, impaired 
      HRQL, and reduced productivity while at work and in daily activities, despite 
      optimized PPI therapy. Mean annual GERD-related costs were US$9944 per patient, 
      comprising total direct costs and mean productivity loss costs of US$4068 and 
      US$5876 per patient, respectively. CONCLUSION: Patients with GERD and a partial 
      response to PPI therapy have considerable direct and indirect costs, along with 
      substantial impairments in HRQL and productivity.
FAU - Stalhammar, Nils-Olov
AU  - Stalhammar NO
AD  - Payer Evidence, AstraZeneca R&D, Molndal, Sweden.
FAU - Spiegel, Brennan M
AU  - Spiegel BM
AD  - Department of Gastroenterology, VA Greater Los Angeles Healthcare System; David 
      Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
FAU - Granstedt Lofman, Helena
AU  - Granstedt Lofman H
AD  - Payer Evidence, AstraZeneca R&D, Molndal, Sweden.
FAU - Karlsson, Maria
AU  - Karlsson M
AD  - Payer Evidence, AstraZeneca R&D, Molndal, Sweden.
FAU - Wahlqvist, Peter
AU  - Wahlqvist P
AD  - Payer Evidence, AstraZeneca R&D, Molndal, Sweden.
FAU - Naesdal, Jorgen
AU  - Naesdal J
AD  - Medical Department, AstraZeneca R&D, Molndal, Sweden.
FAU - Nelson, M Todd
AU  - Nelson MT
AD  - Late Phase, Life Sciences, OptumInsight, Raleigh, NC, USA.
FAU - Despiegel, Nicolas
AU  - Despiegel N
AD  - HEOR, OptumInsight, Nanterre, France.
LA  - eng
PT  - Journal Article
DEP - 20121205
PL  - New Zealand
TA  - Pragmat Obs Res
JT  - Pragmatic and observational research
JID - 101688693
PMC - PMC5045010
OTO - NOTNLM
OT  - GERD
OT  - gastroesophageal reflux disease
OT  - partial response
OT  - proton pump inhibitors
EDAT- 2012/12/05 00:00
MHDA- 2012/12/05 00:01
PMCR- 2012/12/05
CRDT- 2012/12/05 00:00
PHST- 2012/12/05 00:00 [pubmed]
PHST- 2012/12/05 00:01 [medline]
PHST- 2012/12/05 00:00 [entrez]
PHST- 2012/12/05 00:00 [pmc-release]
AID - por-3-057 [pii]
AID - 10.2147/POR.S36704 [doi]
PST - epublish
SO  - Pragmat Obs Res. 2012 Dec 5;3:57-67. doi: 10.2147/POR.S36704. eCollection 2012.